Company: HCTI
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026218
Chunk: 502

Company: Healthcare Triangle, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 3
Chunk 502
---
will be sufficient to meet our working capital requirements over the next 12 months. If sources of liquidity are not available or if we
cannot generate sufficient cash flow from operations during the next twelve months, we may be required to obtain additional sources of
funds through additional operational improvements, capital market transactions, asset sales or financing from third parties, a combination
thereof or otherwise. We cannot provide assurance that these additional sources of funds will be available or, if available, would have
reasonable terms.

Operating Activities

Net cash used in operating activities was $1.08
million for the twelve months ended December 31, 2024, and net cash used in operations was $2.1 million for the twelve months ended December
31, 2023.

Investing Activities

Net cash used in investing activities was $0 million
for the twelve months ended December 31, 2024, and $0.013	 million for the twelve months ended December 31, 2023.

Financing Activities

Cash flows from financing activities was $0.135
million for the twelve months ended December 31, 2024, and $2 million for the twelve months ended December 31, 2023.

Off-Balance Sheet Arrangements

We do not have any relationships with unconsolidated
organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the
purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes as defined by Item 303(a)(4)
of SEC Regulation S-K, as of December 31, 2024.

46

Item 8. Financial Statements and Supplementary Data

HEALTHCARE TRIANGLE, INC.

Consolidated Financial Statements

December 31, 2024 and 2023

  Report of Independent Registered Public Accounting Firm PCAOB ID 2738 F-2  Financial Statements    Consolidated Balance Sheets as of December 31, 2024 and 2023 F-3  Consolidated Statements of Operations For The Years Ended December 31, 2024 and 2023 F-4  Consolidated Statements of Changes in Stockholders’ Equity (Deficit) For The Years Ended December 31, 2024 and 2023 F-5  Consolidated Statements of Cash Flows For The Years Ended December 31, 2024 and 2023 F-6  Notes to Consolidated Financial Statements F-7 

F-1

Report